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Styrene-Associated Health Outcomes at a
Windblade Manufacturing Plant
Anna-Binney McCague, MD,1,2 Jean M. Cox-Ganser, PhD,1 Joshua M. Harney, MS, CIH,3
K. Udeni Alwis, PhD,4 Benjamin C. Blount, PhD,4 Kristin J. Cummings, MD, MPH,1
Nicole Edwards, MS,1 and Kathleen Kreiss, MD1
Background Health risks of using styrene to manufacture windblades for the green
energy sector are unknown.
Methods Using data collected from 355 (73%) current windblade workers and
regression analysis, we investigated associations between health outcomes and styrene
exposure estimates derived from urinary styrene metabolites.
Results The median current styrene exposure was 53.6mg/g creatinine (interquartile
range: 19.5–94.4). Color blindness in men and women (standardized morbidity ratios 2.3
and 16.6, respectively) was not associated with exposure estimates, but was the type
previously reported with styrene. Visual contrast sensitivity decreased and chest tightness
increased (odds ratio 2.9) with increasing current exposure. Decreases in spirometric
parameters and FeNO, and increases in the odds of wheeze and asthma-like symptoms
(odds ratios 1.3 and 1.2, respectively) occurred with increasing cumulative exposure.
Conclusions Despite styrene exposures below the recommended 400mg/g creatinine,
visual and respiratory effects indicate the need for additional preventative measures in
this industry. Am. J. Ind. Med. 58:1150–1159, 2015.  2015 Wiley Periodicals, Inc.
KEY WORDS: styrene; occupational exposure; color vision defects; contrast
sensitivity; spirometry
INTRODUCTION
The manufacture of power-generating wind turbines,
complex machines that include composite material
windblades, is a relatively new industry that employed
30,000 workers in the United States in 2011 and is expanding
rapidly with the increased focus on renewable energy sources
[Platzer, 2012]. A previous investigation at the windblade
manufacturing facility that is the subject of this study
documented high inhalational exposures to styrene [Ham-
mond et al., 2011]. Styrene, an aromatic hydrocarbon derived
from benzene, is a colorless, volatile liquid with a sweet
smell. It is used widely in the synthesis and manufacture of
polystyrene, hundreds of different copolymers, and other
industrial resins [NTP, 2014]. The highest potential
exposures to styrene occur in the production of reinforced
plastics [ATSDR, 2010], in which fibers of glass or other
materials are used to enhance the strength and resistance of
plastics. Fiberglass-reinforced plastics (often called simply
“fiberglass” materials) are made with styrene as a cross-
linking agent in polyester resins used in gel-coating and
laminating operations; the resins generally contain between
30% and 50% styrene by weight [NTP, 2014]. Fiberglass
products traditionally have included boats, bathtubs, shower
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stalls, tanks, and drums [NTP, 2014] and, more recently,
some windblades [Platzer, 2012].
Styrene is associated with neurotoxic effects and
respiratory effects [Chmielewski and Renke, 1975; Brigham
and Landrigan, 1985; Moscato et al., 1987; Kolstad et al.,
1995]. Notably, there are recent case reports of obliterative
bronchiolitis in England and Taiwan in the fiberglass boat
andwater tank industries, which share similar exposures with
fiberglass windblade manufacture [Chen et al., 2013;
Cullinan et al., 2013].
A recent effort to decrease styrene exposures at this
windblade manufacturing facility had been prompted by
the documentation of high peak exposures (>100 part per
million [ppm]) during task-based sampling [Hammond et al.,
2011]. The facility had eliminated the highest exposure tasks,
increased exhaust ventilation, increased respiratory protec-
tion, and changed from a gelcoat with 36–42% styrene
[Hammond et al., 2011] to one with a lower percentage of
styrene. In follow-up, the company requested that the
National Institute for Occupational Safety and Health
(NIOSH) conduct a health hazard evaluation of current
workplace exposures and health effects. Prior to the medical
survey, we evaluated airborne styrene concentrations at the
plant. On 3 consecutive days, we collected 74 full-shift air
samples for styrene in the breathing zone of production
workers. The styrene concentrations ranged from <1 ppm
to 51 ppm, with a median of 7 ppm. Only one of five
departments that used styrene had concentrations above
the NIOSH recommended exposure limit of 50 ppm for up to
a 10-hr time weighted average, or the American Conference
of Governmental Industrial Hygienists (ACGIH1) Thresh-
old Limit Value1 of 20 ppm averaged over an 8-hr workday,
during a 40-hr workweek [ACGIH, 2011]. In this depart-
ment, employees manually reinforced and patched the
blades, both interior and exterior, using sheets of styrene
resin-containing fiberglass.
Styrene is rapidly absorbed and eliminated, appearing
in the blood immediately after the start of exposure and
declining precipitously after the end of exposure [ACGIH,
2011]. The vast majority (90–97%) of absorbed styrene is
eliminated as urinary metabolites, primarily mandelic acid
and phenylglyoxylic acid [ACGIH, 2011]. Urinary elimina-
tion of these metabolites is biphasic, with half-times up to 10
and 40 hr [ACGIH, 2011]. Thus, the biologic exposure
estimate for assessing urinary metabolites of styrene reflects
acute, rather than chronic, exposure. Biological monitoring
has advantages over air monitoring in understanding dose
when multiple routes of exposure exist and respiratory and
skin protection are used. To protect styrene-exposed workers
from neurotoxic effects and ocular and respiratory irritation
(not respiratory disease), the ACGIH has recommended an
end-of-shift biologic exposure index (BEI1) maximum of
400mg of styrene metabolites (mandelic acidþ phenyl-
glyoxylic acid) per gram (mg/g) of creatinine in the urine
[ACGIH, 2011]. ACGIH estimates this BEI corresponds to
an inhalation exposure at the TLV for styrene of 20 ppm
averaged over an 8 hr workday, during a 40-hr workweek
[ACGIH, 2011].
At the time of our study, this windblade manufacturing
plant employed about 500 people who worked in shifts
ranging from 8 hr to 12 hr. The number of people employed
varied in recent years from 300 to 900, depending on market
fluctuations. Many employees had been laid off and rehired,
leading to gaps in their employment history.
Employees sprayed styrene-containing gelcoat into a
clamshell-like mold, and then laid down balsa wood and
fiberglass to form the blade structure. Employees bound the
layers together with a styrene-based resin, infused in a closed
process. The two halves of the blade were then closed
together with styrene-containing glue and transported to
another department for further refinements and repairs. There
employees sanded the blade and placed pieces of fiberglass
over errors and weak areas, both inside and outside the blade,
and coated the repairs with styrene-based resin. Finally, each
blade was painted with styrene-based paint, balanced, and
finished. Workers with the same job title often performed
different tasks, or changed primary tasks on a regular basis,
leading to varying exposures from day-to-day or week-to-
week.
To explore the visual and respiratory effects of styrene,
and understand the current risk to workers at this facility, we
conducted a cross-sectional study. We aimed to understand
exposures using styrene biomarkers and compare these to
health outcomes including color and contrast vision,
respiratory symptoms, and lung function.
MATERIALS AND METHODS
Data Collection
The study was conducted in accordance with the NIOSH
Institutional Review Board’s policies for health hazard
evaluations. Every worker currently employed was invited to
participate in testing during the week of the study in
July 2013. After providing written informed consent, each
participant was interviewed with a computer-based ques-
tionnaire addressing respiratory symptoms, medical diagno-
ses, smoking history, work history, personal protective
equipment (PPE) use, and demographic information. The
respiratory health questions were adapted from validated
survey instruments [Ferris, 1978; DHHS, 1996; Grassi et al.,
2003].
We assessed visual acuity using a Rosenbaum pocket
vision screener. The Lanthony desaturated D-15 (Gulden
Ophthamalics, Elkins Park, PA), a color arrangement test
recommended for detecting acquired vision loss [Fox and
Boyes, 2001], was administered binocularly with daylight
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filtering glasses. The caps were randomly clustered on the
test surface; workers were asked to arrange the caps in color
order by finding the cap closest in color to the reference cap
and placing it nearby. They then continued for all 15 caps.
Visual contrast sensitivity was tested monocularly with the
functional acuity contrast test (FACT; Stereo Optical
Company, Inc.; Chicago, IL), under conditions specified in
the manual [Ginsburg, 1993].
Fraction of exhaled nitric oxide (FeNO) and lung
functionwere assessed followingAmerican Thoracic Society
(ATS) guidelines [Miller et al., 2005; Dweik et al.,
2011] using the NIOX Mino© device for exhaled nitric
oxide (Aerocrine; Solna, Sweden), and a dry rolling-seal
spirometer. Repeat spirometry after administration of a
bronchodilator was offered to any participant with an
abnormal test. FeNO is associated with eosinophilic airway
inflammation as often occurs with asthma and FeNO levels
rise with exposure to allergens or other asthma triggers
[Dweik et al., 2011]. Before FeNO was measured,
participants were asked about potential confounders, includ-
ing food and drink intake, smoking, recent illness, exercise,
and steroid use. They were allowed six tries, and the first
acceptable trial was used.
End-of-shift urine samples were assayed for mandelic
acid (MA), phenylglyoxylic acid (PGA), and a third styrene
metabolite, N-acetyl-S-(1-phenyl-2-hydroxyethyl)-L-cysteineþ
N-acetyl-S-(2-phenyl-2-hydroxyethyl)-L-cysteine (PHEMA) us-
ing ultra high performance liquid chromatography (Waters, Inc.,
Milford, MA) coupled with an electrospray ionization triple
quadrupole mass spectrometry (Sciex API 5500 Triple Quad,
Applied Biosystems, Foster City, CA) [Alwis et al., 2012].
Together, MA, PGA, and PHEMA represent the major products
of styrene metabolism in humans. The limits of detection were
12ng/ml forMA, 12ng/ml for PGA, and 0.7 ng/ml for PHEMA.
Urine creatinine was measured using the enzyme colorimetric
method with the automated Roche/Hitachi Modular Analytics
system, allowing us to normalize results to individual kidney
function. More detailed information about the analyses of
urine samples is available in the Online Supplement.
Statistical Methods
Statistical analyses were conducted using SAS
software version 9.3 and JMP software version 10.0.1
(SAS Institute, Inc., Cary, NC). We chose a P-value of
0.05 for statistical significance, and P 0.1 for borderline
statistical significance.
For comparison to the BEI, we calculated a biologic
exposure measurement for current styrene exposure for each
individual by summing milligrams of MA and PGA, and
dividing by grams of creatinine. To reduce the effect of
outlier variables, we log-transformed (using the natural log)
the current styrene exposure to compare it to our health
outcomes using linear and logistic regression models. We
compared the odds of symptoms and health outcomes in
workers with a current styrene exposure above or equal to the
median to those with exposure below the median.
To estimate workers’ styrene exposure over the course of
their work history at this plant, an average current styrene
exposure was assigned to each department/job title combi-
nation based on those workers who participated in the study.
For those job titles without an average current styrene
exposure, we assigned one from another job in the same or a
nearby department. These average current styrene exposures
were then multiplied by the number of months a worker had
spent in that job and summed to give a relative indicator of
cumulative styrene exposure.
Asthma-like symptoms were defined as any of the
following: current use of asthma medicine, wheezing or
whistling in the chest in the past 12months, awakening with a
feeling of chest tightness in the past 12 months, or attack of
asthma in the past 12 months [Grassi et al., 2003]. For all
symptoms (including those mentioned above, eye irritation,
nasal irritation, shortness of breath, usual cough, and usual
phlegm), we calculated standardizedmorbidity ratios (SMRs)
and 95% confidence intervals (CI) through comparisons with
data obtained from the US population from the ThirdNational
Health and Nutrition Examination Survey (NHANES III)
[DHHS, 1996], using indirect standardization for race (white
or black), sex, age (17–39or40years) and cigarette smoking
(ever/never). We compared symptoms to styrene exposure
(the natural log of our current and cumulative exposure
markers) using logistic regression to calculate odds ratios
(OR) and corresponding 95%CI, and controlled for smoking
(current, former, never), gender, race, and age.
For color vision, using the published guidelines each
participant was assigned a color confusion index (CCI) and a
color angle [Geller, 2001; Toruk, 2014]. A CCI >1.65 was
considered abnormal color vision, and the color angle then
determined the type of color vision deficit (protan [red–
green], deutan [red–green], tritan [blue–yellow], or other
[unknown type]). We calculated SMRs comparing the
prevalence of color vision abnormalities with those expected
in a western population [Kalloniatis and Luu, 2007].We used
linear and logistic regression models to assess associations
between exposure variables and both CCI and type of color
blindness. We also evaluated grouped color vision categories
(protan/deutan, tritan/unknown, and normal color vision),
given that protan and deutan color vision deficits are
typically congenital, tritan is more commonly acquired, and
unknown could represent the combination of a congenital
and an acquired deficit or more than one acquired deficit.
Some literature suggests that occupational color blindness
may be progressive, beginning with blue–yellow, and
developing through combined blue–yellow and red–green
color blindness to complete color vision loss [Geller and
Hudnell, 1997; Fox and Boyes, 2001].
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For visual contrast sensitivity, we created a score at each
frequency (1.5, 3, 6, 12, and 18 cycles/degree [CPD]) for
each participant by averaging the left and right eye scores
[Ginsburg, 1993]. Using linear regression models, we looked
for an association between visual contrast sensitivity and the
exposure variables. All vision models were controlled for
visual acuity, diabetes, glaucoma, macular degeneration,
cataracts, age, alcohol consumption in the last 24 hr (as a
surrogate for overall alcohol consumption), and smoking; for
consistency with prior literature, we report the fully adjusted
results. The B-estimate is a slope relating the contrast score
and log of exposure (current styrene exposure or cumulative
styrene exposure) given by the linear regression model; it
was converted to an effect for the un-logged variables by
multiplying the B-estimate by ln (101/100), giving our effect
estimate for a 1% increase in the current styrene exposure or
cumulative styrene exposure. To give a better sense of the
impact of such a change, we calculated the absolute change in
visual contrast with an increase in exposure from the 2.5th to
97.5th percentile [Cornell Statistical Consulting Unit, 2012].
FeNO results above 50 parts per billion (ppb) were
considered abnormal and those between 25 ppb and 50 ppb
were considered intermediate, according to the ATS guide-
lines [Dweik et al., 2011]. FeNO values below the limit of
detection (LOD) were estimated using the formula LOD/
(√2). We used the FeNO value as a continuous outcome
variable in linear models to assess the relationship with
exposure variables. We adjusted the models for age, smoking
status, respiratory illness in the last 7 days, and ingestion of
nitrate-rich foods. As described above, we also calculated an
effect estimate and an absolute change in FeNO with a
change in exposure from 2.5th to 97.5th percentile.
Spirometry was interpreted based on prediction equa-
tions to define normal values for forced expiratory volume in
1 s (FEV1), forced vital capacity (FVC), and the ratio of the
two (FEV1/FVC) [Hankinson et al., 1999]. We defined
obstruction as a value of FEV1/FVC below the lower limit of
normal, restriction as FVC below the lower limit of normal,
and the combination of both low values to define a mixed
pattern of obstruction and restriction [Pellegrino et al., 2005].
The prevalence of workers with obstruction, restriction, or a
mixed pattern on spirometry was compared to population
values from NHANES III with SMRs. Associations between
the biologic exposure measures and spirometry outcomes
were investigated using linear regression models adjusted for
smoking, body mass index (BMI), and in the case of FEV1/
FVC, age. As with the visual contrast scores and FeNO
outcomes, we converted the B-estimate to an effect estimate,
and then calculated the absolute change in outcome with a
change in exposure from the 2.5th to 97.5th percentile.
In this paper, we present results of analyses using current
and cumulative styrene exposure metrics that were based on
the biological exposuremeasurement (sum ofMA and PGA).
We also developed models using current and cumulative
styrene exposure metrics that were based on the individual
urinary metabolites (MA, PGA, and PHEMA alone). These
single-metabolite models generally had similar estimates to
those of the biological exposure measurement, so are not
reported.
RESULTS
Overall, 355 (73%) of 486 eligible workers participated
in at least one component of the study. Most participants
completed most of the testing offered, including the question-
naire (n¼ 354; >99%) vision testing (n¼ 352; 99%), FeNO
measurement (n¼ 341; 96%), spirometry (n¼ 343; 97%),
and urine styrene metabolite analysis (n¼ 322; 91%).
Bronchodilator was administered to 24 participants with
obstruction on spirometry testing. The workforce was largely
young, white and male, with short tenures, and a high
proportion of current and former smokers (Table I).
Symptom frequencies are shown in Table II. Eye
symptoms, shortness of breath, usual cough, and usual
phlegm were less common than expected from adjusted
comparisons with the US adult population, while other
TABLE I. Demographic Characteristics and Styrene Exposure ofWind-
bladeManufacturing PlantWorkers
Demographic Characteristic (n¼ 354)a Value
Age, years, mean (range) 37.5 (19^65)
Male, n (%) 269 (75.9)
Race, n (%)
White 263 (74.3)
Black 46 (13.0)
American Indian orAlaska Native 20 (5.7)
Other 4 (1.1)
More than one race 14 (4.0)
Missing 7 (2.0)
Smoking status, n (%) 142 (40.1)
Current 78 (22.0)
Former 134 (37.9)
Never 4.8, 5.5 (<1^22.7)
Tenure, years, mean, median (range)b
Styrene Exposure (n¼ 322)a Mean, median (range)
Current styrene exposure,c mg/g creatinine 69.5, 53.6 (0.7^941.0)
Cumulative styrene exposure,d mg-months/g
creatinine
3945, 2426 (10.7^69800)
a354workerscompletedthequestionnaire,providingdemographic information;322
workers provided a urine sample.
bTenure was calculated by summing all time employed at the plant. Gaps in employ-
ment (such asdue to layoffs andrehiring)werenot included in the tenure calculation.
cUrinarymandelic acidþ phenylglyoxylic acid.
dCalculated for 354 participants using average current styrene exposure for a job
multipliedbyanindividual’s jobtenureinmonthsandsummingacrossthejobsheldby
an individual, if applicable.
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symptoms and self-reported lifetime asthma diagnosis
(n¼ 26; 7.3%) were about as common as expected (data
not shown). The average percent of predicted FEV1 and FVC
were within the normal range (Table II), and the prevalences
of spirometric abnormalities were not elevated compared to
the reference population (data not shown). Among partic-
ipants with obstruction, 13 (46%)were current smokers and 7
(25%) were former smokers, with mean age of 42 years
(range 29–63) and mean pack-years of 18.5 (range <1–47).
Twenty-four workers with obstruction were given a
bronchodilator. Five (21%) of these had reversible obstruc-
tion; 14 (74%) of those with fixed obstruction were current or
former smokers. Just three participants had a FeNO result
which was classified as abnormal (>50 ppb), while over half
(n¼ 184; 52%) had abnormal visual contrast sensitivity; 8%
(n¼ 7) of female workers and 18% (n¼ 49) of male workers
had abnormal color vision. Fifteen men reported a history of
doctor-diagnosed color blindness; 11 (73%) of these had
abnormal color vision on our testing. Thus, most of those
identified as having abnormal color vision did not report a
history of doctor-diagnosed color blindness.
Styrene exposure (assessed through urine biomarkers)
varied widely throughout the plant. The mean current styrene
exposure was 69.5mg/g creatinine, with a range of
0.7–941.0mg/g creatinine (Table I). The median was
53.6mg/g creatinine, and the interquartile range was
TABLE II. Symptoms and Lung FunctionTest Results of 355WindbladeManufacturing PlantWorkers, Overall andbyMedian Current and Cumulative
Styrene Exposure
By median styrene exposure
Current (mg/g creat) Cumulative (mg-months/g creat)
Overall <53.6 53.6 <2,426.4 2,426.4
Symptom, n (%)a
Shortness of breath 44 (12.4) 19 (11.8) 22 (13.7) 17 (9.6) 27 (15.3)
Usual cough 43 (12.1) 20 (12.4) 20 (12.4) 21 (11.9) 22 (12.4)
Usual phlegm 39 (11) 17 (10.6) 19 (11.8) 20 (11.3) 19 (10.7)
Wheeze 79 (22.3) 35 (21.7) 39 (24.2) 31 (17.5) 48 (27.1)
Chest tightness 31 (8.9) 8 (5.0) 21 (13.0) 16 (9.0) 15 (8.5)
Asthma-like symptoms 98 (27.7) 41 (25.5) 52 (32.3) 41 (23.2) 57 (32.2)
Nasal symptoms 182 (51.4) 89 (55.3) 77 (47.8) 79 (44.6) 103 (58.2)
Eye symptoms 108 (30.5) 49 (30.4) 52 (32.3) 42 (23.7) 66 (37.3)
Spirometry, n (%) or meanb
Obstruction 28 (8.2) 15 (9.3) 9 (5.6) 9 (5.1) 19 (10.7)
Restriction 16 (4.7) 10 (6.5) 6 (3.8) 10 (5.9) 5 (3.5)
Mixed 3 (0.9) ç ç ç ç
Any abnormality 47 (13.7) 26 (16.2) 17 (10.6) 19 (10.7) 28 (15.8)
%predicted FEV1 99.9 99.7 100.7 100.7 98.9
% predicted FVC 102.5 102.4 103.0 102.5 102.3
% predicted MMEF 96.4 95.8 98.1 98.7 94.1
FEV1/FVC % 79.2 78.6 79.8 80.3 78.1
FeNO, n (%) or mean
FeNO result, ppb 13.5 14.5 12.9 14.3 12.8
FeNO>25 ppb 30 (8.8) 15 (9.4) 13 (8.6) 17 (10.0) 13 (7.6)
creat, creatinine; FEV1, forced expiratory volume in1s; FVC, forced vital capacity; FeNO, fraction of exhaled nitric oxide; MMEF, maximal mid-expiratory flow; ppb, parts
per billion.
Statistically significant differences (P 0.05) are in bold.Borderline statistically significant differences (0.05< P 0.1) are in italics.
A total of 355workers participated in at least one component of the study. For the results presented, the denominator ranged from 310 to 354, depending on participation
in the health assessment component and the urine styrenemetabolite analyses.
aShortness ofbreathwas definedaswhenhurryingon level groundorwalkingup a slight hill.Wheeze, chest tightness, nasal symptoms (stuffy, itchy, or runny nose), andeye
symptoms(watery, itchyeyes)werereportedfor the last12months.Asthma-likesymptomsweredefinedasanyof thefollowing: currentuseofasthmamedicine,wheezing,or
whistling in the chest in the past12months, awakeningwith a feeling of chest tightness in the past12months, or attack of asthma in the past12months.
bObstructiondefinedasFEV1/FVCbelowthelowerlimitofnormal,restrictiondefinedasFVCbelowthelowerlimitofnormal,mixeddefinedasbothFEV1/FVCandFVCbelowthe
lower limit of normal.Mixeddefectswere not stratifiedbymedian styrene exposure due to the small numberof participantswith this physiology; the corresponding cells are
markedwithç.
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19.5–94.4mg/g creatinine. Only one participant exceeded
the ACGIH recommended BEI of 400mg/g creatinine. The
mean cumulative styrene exposure was 3,945mg-month/g
creatinine (Table I).
The prevalence of some symptoms differed by styrene
exposure (Table II). Participants with a current styrene
exposure greater than or equal to the median had higher odds
of chest tightness than participants with a current styrene
exposure below the median (OR 2.9, CI 1.2–6.7). Cumulative
styrene exposure was associated with greater odds of wheeze
(OR 1.3, CI 1.1–1.5), nasal symptoms (OR 1.2, CI 1.1–1.4),
eye symptoms (OR 1.2, CI 1.1–1.4), and asthma-like
symptoms (OR 1.2, CI 1.0–1.4). Since the models were run
using the natural log of the cumulative exposure estimate,
these ORs represent the change in odds of each symptomwith
a 2.7-fold change in the untransformed cumulative exposure.
The prevalences of both deutan and protan color
deficiencies (red–green color blindness) in the workforce
were similar to expected levels (Table III). Tritan color
blindness (blue–yellow) is rare, and the prevalence of tritan
color blindness in this workforce was elevated compared to
the prevalence in the reference population (Table III).
Because there is no information on expected prevalence of
unknown abnormalities, SMRs could not be calculated for
this outcome. The prevalence of color blindness overall was
significantly elevated in both men and women at the plant
(Table III). None of the color vision outcomes was associated
with the markers of styrene exposure (not shown).
Visual contrast outcomes at 1.5, 3, 6, and 12 CPD were
significantly related to the natural log of current styrene
exposure in adjusted models (Table IV). This effect was
strongest at 6 cycles/degree (Table IV). Visual contrast
scores fell an estimated 8.8–22.1 points from the 2.5th to
97.5th percentile of untransformed current styrene exposure,
that is, from 2.8mg/g to 242.0mg/g creatinine (Table IV).
The prevalence of obstruction on spirometry was
significantly higher and the FEV1/FVC ratio significantly
lower in participants with cumulative styrene exposure
greater than or equal to the median (Table II). In regression
models, cumulative styrene exposure was inversely associ-
ated with spirometric parameters (Table V). The reductions
in both percent of predicted maximal mid-expiratory flow
(MMEF) and FEV1/FVC were significant (Table V), while
the reduction in percent of predicted FEV1 was borderline
significant. The percent of predicted FVC was not associated
with cumulative styrene exposure (Table V).
Cumulative styrene exposure was also inversely
associated with FeNO in an adjusted model (Table V). We
repeated the analysis looking at non-smokers only and found
a similar trend (data not shown).
Certain health outcomeswere correlatedwith each other,
including decreased FEV1/FVC and the presence of asthma-
like symptoms (P< 0.0001), and CCI and visual contrast
sensitivity at 6 CPD (P¼ 0.02). The CCI was not associated
with FEV1/FVC, the percent of predicted MMEF, or FeNO,
and tritan color blindness was not associated with spirometry
interpretation, or percent of predicted FEV1 or MMEF.
Visual contrast sensitivity at 6 CPD (the frequency affected
TABLE III. Color Vision Abnormalities inWorkers at aWindblade
Manufacturing Plant (n¼ 352)
n
Observed,
n (%)
Expecteda,
n (%) SMR 95%CI
Protan
Male 268 8 (3.0) 5.4 (2.0) 1.5 0.6^2.9
Female 84 0 0.02 (0.02) a a
Deutan
Male 268 10 (3.7) 17.5 (6.5) 0.6 0.3^1.1
Female 84 0 0.3 (0.4) a a
Tritan
Male 268 7 (2.7) 0.03 (0.01) 270 105^536
Female 84 3 (3.6) 0.01 (0.01) 360 73^1031
Unknown
abnormality
Male 268 24 (9.0) n/a b b
Female 84 4 (4.8 n/a b b
Any abnormalityb
Male 268 49 (18.3) 21.5 (8.0) 2.3 1.7^3.0
Female 84 7 (8.3) 0.4 (0.5) 16.6 6.6^33.9
SMR, standardized morbidity ratio (based on percentages); CI, confidence interval;
n /a, not available; a, unable to calculate because number observed was zero;
ß, unable to calculate because population values do not exist.
aExpectedpercentages from literature [Geller and Hudnell, 1997].
bAny abnormality was defined as having a protan, deutan, tritan, or unknown color
vision abnormality.
TABLE IV. AdjustedModels of the Relationship BetweenVisual Con-
trast Sensitivity and Log-Transformed Current Styrene Exposure Esti-
mates AmongWindbladeManufacturingWorkers (n¼ 351)
Frequency
Effect
estimate
 ,a P-valueb
Change in outcome
with current exposure
change from 2.5th to
97.5th percentileb
1.5 cpd 0.020 0.04 8.8
3 cpd 0.034 0.03 15.6
6 cpd 0.049 <0.01 22.1
12 cpd 0.030 0.04 13.2
18 cpd 0.015 0.06 6.7
cpd, cycles per degree.
Models were adjusted for age, smoking status, glaucoma, cataracts, macular de-
generation, alcoholic consumption during last 24 hr, and visual acuity (of which
only age and acuity were significant).
aEffect change per1% change in current styrene exposure.
bBoldedP-values and estimates are statistically significant.
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most by styrene) was not associated with FeNO, FEV1/FVC,
percent of predicted MMEF, or spirometry interpretation.
DISCUSSION
In a windblade manufacturing workforce without excess
symptoms or spirometric abnormalities overall, we found
associations between estimates of current and cumulative
styrene exposure based on urine styrene metabolites and
adverse vision and respiratory outcomes. We also found an
excess of color vision abnormalities in the workforce that
was not associated with exposure estimates.
The excess of color vision abnormalities in this
workforce is striking and is likely related to occupational
exposure, despite the lack of association with exposure
variables in this study. Animal and human studies have
linked the pathophysiology of acquired color blindness to
styrene exposure, reporting that solvents such as styrene lead
to blue–yellow (or tritan) color blindness, with red–green
color blindness additionally occurring after further exposure
[Geller and Hudnell, 1997; Vettori et al., 2000; Fox and
Boyes, 2001; Kishi et al., 2001; Iregen et al., 2004]. The
impact on blue–yellow color vision comes from outer retinal
changes caused by the solvents, while red–green is secondary
to optic nerve and central pathway damage [Fox and Boyes,
2001; ACGIH, 2011]. The prevalence of all types of color
blindness in the plant was more than twice as high as
expected, and the excess was mostly found in the tritan group
and the unknown group (which may represent a combination
of two or more abnormalities, as might be seen in progressive
occupational color blindness). The majority of prior studies
found blue–yellow color abnormalities in workers with
exposures higher than those in our study, some of whom did
not wear any respiratory protection [Eguchi et al., 1992;
Campagna et al., 1995; Castillo et al., 2001; Kishi et al.,
2001; Iregen et al., 2004]. If the color vision abnormalities
reflect current styrene exposures, our study suggests that the
effect threshold may be lower than previously thought and
that current respirator use in this plant may not protect
against color vision loss; furthermore, the high prevalence of
unknown abnormalities may reflect complex color vision
loss that deserves further study.
There are several reasons why our study may not have
shown an association between color blindness and exposure
estimates. The correlation of color blindness and visual
contrast suggests that the samemechanismmay be impacting
both, but that there is something complicating the relation-
ship between color vision and styrene exposure. Past studies
have indicated that there may be some reversibility in color
blindness when styrene exposure is decreased [Castillo et al.,
2001; Triebig et al., 2001; Seeber et al., 2009]. Because of the
changes at the plant and gaps in employees’ work histories,
such reversibility may have impacted our results. Further-
more, most exposures were clustered in a tight group well
below the BEI of 400mg/g creatinine; despite log-
transformation of exposure variables, this clustering may
have obscured our ability to see a dose–dependent relation-
ship. Few workers at this plant were unexposed to styrene; if
the effect threshold is lower than initially thought, it might be
that we did not have a large enough sample of workers with
minimal exposures to see a relationship between exposure
and color vision. The large number of recent hires in high
exposure areas may have impacted our results because such
workers may not have been working long enough to show
color vision changes that were classified as abnormal. Lastly,
our use of binocular testing may have misclassified people
with monocular acquired deficits as normal and obscured
associations with exposure.
Current styrene exposure was related to visual contrast
sensitivity at intermediate and low frequencies. The effect
was strongest at the intermediate frequency of 6 cycles/
degree, which supports prior literature reporting contrast
sensitivity loss at intermediate and high frequencies due to
neurologic injury from solvent exposure [Castillo et al.,
2001; Waksman and Brody, 2007]. Furthermore, contrary to
some studies, our findings support an association between
contrast vision loss and current, rather than cumulative,
exposure [Castillo et al., 2001].
Chest tightness in the past 12 months was nearly
three times more common in workers with a current styrene
exposure greater than or equal to the median than in those
TABLE V. Lung Function Parameters and the Natural Log of Cumulative
Styrene Exposure Estimates inWorkers at aWindbladeManufacturing
Plant
Lung function
measure
Effect
estimate
a,b
P-valueb
Change in outcome
with cumulative exposure
change from 2.5th to
97.5th percentileb
FEV1/FVCc 0.006 0.015 3.5
Percent of
predicted FEV1d
0.008 0.079 5.0
Percent of
predicted MMEFd
0.026 0.011 15.6
Percent of
predicted FVCd
0.002 0.7 0.93
FeNOe 0.009 0.0013 5.54
FEV1, forced expiratory volume in one second; FVC, forced vital capacity; MMEF,
maximal mid-expiratory flow; FeNO, fraction of exhaled nitric oxide; BMI, body
mass index.
aEffect change per1% change in cumulative styrene exposure.
bBolded results are statistically significant.
cModel adjusted for age, smoking status, and BMI.
dModel adjusted for smoking status and BMI.
eModel adjusted for smoking status, respiratory illness, consumption ofnitrate-rich
foods, gender, and age.
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below. For workers with higher cumulative exposure to
styrene, symptom relationship to exposure was also noted,
although effects were not as large; asthma-like symptoms
reached statistical significance, as did wheeze, nasal
irritation, and eye irritation. These findings support prior
literature which indicates styrene may be a respiratory
irritant and a cause of occupational asthma [Moscato et al.,
1987; Helal and Elshay, 2012], as such symptoms are
consistent with both asthma and other obstructive lung
diseases such as obliterative bronchiolitis. Furthermore,
workers with asthma-like symptoms had decreased FEV1/
FVC, which indicates that workers with subjective symp-
toms also may have objective findings on examination. Such
exposure-related symptoms were seen despite the absence
of excess symptoms in the workforce overall (possibly
secondary to the healthy worker effect), indicating increased
focus on protection from exposure may be warranted.
The possibility of styrene-associated lung disease was
further reinforced by the association between cumulative
styrene exposure and spirometric parameters. FEV1/FVC
below the lower limit of normal indicates an obstructive lung
problem; a decreased ratio that nevertheless remains within
the range of normal may represent an early change in the
development of obstruction. In this workforce with other
evidence of the healthy-worker effect, the lack of excess
abnormal tests does not negate the importance of decreasing
FEV1/FVC associated with increasing cumulative styrene
exposure. Furthermore, the significant impact on percent of
predicted MMEF suggests that the small airways are
involved [Burgel, 2011]. Almost 80% of workers with
obstruction who were given a bronchodilator had no
significant change in their test parameters, which is
consistent with fixed obstructive lung disease, including
obliterative bronchiolitis. In a cross-sectional study of adults
ages 40–79, 64% of those with obstruction did not respond to
a bronchodilator [Doney et al., 2014], suggesting that fixed
obstruction in our younger study population was higher than
expected. The majority of participants with fixed obstruction
were current or former smokers. Nonetheless, the relatively
young ages and limited smoking histories make it difficult to
attribute these abnormalities solely to smoking.
A link between styrene and obliterative bronchiolitis
was suggested recently by two case series which described
eight workers employed in the reinforced plastics industry
(primarily boatbuilding) who had obliterative bronchiolitis, a
rare irreversible lung disease [Chen et al., 2013; Cullinan
et al., 2013]. Additionally, a large epidemiologic study
described excess mortality from obstructive lung disease in
highly exposed, short-term reinforced-plastics workers,
which would be consistent with obliterative bronchiolitis
[Collins et al., 2013; Cummings et al., 2014]. Furthermore,
an occupational study in an Egyptian reinforced plastics
factory found that styrene exposure correlated with
decreased pulmonary function tests, including FEV1/FVC
and percent of predicted FEV1, FVC, and MMEF, indicating
that obstruction, especially mid-flow obstruction, might be a
consequence of styrene exposure [Helal and Elshafy, 2012].
Animal studies support such respiratory findings; they have
demonstrated that mice exposed to 40–160 ppm of styrene
for 2 years had pathologic changes, including respiratory
metaplasia of olfactory epithelium, decreased olfactory
fibers, decreased eosinophilic staining of Clara cells in
terminal bronchioles, and bronchiolar epithelial hyperplasia
in alveolar ducts [Cruzan et al., 2001].
FeNO is an indirect marker of eosinophilic airway
inflammation that may be increased in asthma [Pala et al.,
2011; Quirce et al., 2012]. In patients with refractory asthma,
low FeNO levels have been found to be associated with the
presence of neutrophils in the sputum [Tseliou et al., 2010].
In our study, FeNO correlated inversely with cumulative
styrene exposure, indicating that higher cumulative exposure
(estimated through urine biomarkers and job history) was
associated with less eosinophilic inflammation. Past studies
have suggested that styrene could be associated with airway
inflammation and asthma [Chmielewski and Renke, 1975;
Moscato et al., 1987; Helal and Elshay, 2012] but to our
knowledge, none have examined the type of inflammation.
Thus, our finding of lower FeNO with increasing cumulative
styrene exposuremay reflect the development of neutrophilic
(rather than eosinophilic) inflammation in the airways with
styrene exposure, which could be associated with asthma
or other airways disease. It is notable that in a study of
microwave popcorns workers at risk for diacetyl-related
obliterative bronchiolitis, participants with higher flavoring
exposures had lower FeNO levels [Akpinar-Elci et al., 2006].
Thus, it is difficult to say whether there was a styrene-
associated increase in asthma in this workforce, though the
predominance of fixed obstruction may indicate that asthma
is not a primary respiratory consequence of styrene exposure.
Limitations of this study include a potential under- or
overestimation of current styrene exposure. Though the
current recommendation is to collect urine at the end of
shifts, as this correlates well with levels of styrene in the air
[ACGIH, 2011], to our knowledge this has not been
explicitly studied in workplaces with periodic exposures,
such as are seen in this workplace. In addition, due to the
changing nature of workers’ tasks, the measurements on the
day of the test may not have represented current exposure
beyond the date of the test. Finally, the BEI was established
under the assumption of 8-hr shifts and a 40-hr workweek
[ACGIH, 2011]. Extended duration shifts and overtime hours
may have occurred for some participants during our study,
but were not formally quantified, and their impact on styrene
exposure estimates is not known.
Some other important considerations include the
significant changes in exposure over the past several years
at the plant, which may have led to an underestimation
of cumulative styrene exposure. Though we treated this
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variable as an indication of relative exposure during work at
the plant, this may have been misleading, as reductions were
probably not uniform across the plant. Furthermore, the
common occurrence of layoffs and rehires could have easily
impacted some of our outcomes (such as color blindness), as
such gaps may leave time for employees to recover from
exposures. For a small number of workers who were English
language learners, the language barrier may have been a
problem. All participants spoke English well enough to
follow directions in the workplace and answer simple
questions, but some may have struggled with certain
instructions. Additionally, workers who were rehired might
have been healthier or less susceptible to the effects of
styrene than workers who previously worked at the plant but
were not rehired, reflecting survivor bias.
Strengths of this study include the large workforce with
styrene exposure, the participation rate of 73%, and the use of
biological markers to measure exposure. With this work-
force’s wide and varied use of PPE, air styrene measure-
ments, while useful to target high-risk areas and determine
the need for PPE, are not as useful in trying to link health
effects to exposures. Biologic exposure markers may be
more efficient and accurate than air monitoring estimates of
exposure doses.
Our finding of associations between styrene biomarkers
and health outcomes suggest that styrene may have health
effects below previously identified thresholds. Our review of
chemicals in use at the plant did not identify other potential
causative exposures. Yet it is possible that styrene may be a
marker for another chemical source of health effects, or that
some of our effects are due to co-exposures to styrene and
other workplace chemicals or dust. However, when added to
the evolving evidence of sentinel cases, mortality studies,
animal experiments, and cross-sectional workforce studies,
this study certainly supports the presence of health hazards in
the reinforced plastics industry and a role for styrene as an
exposure of concern.
In summary, the association of health outcomes
including decreased visual contrast, decreased lung function,
and increased respiratory symptoms with styrene exposure
below the ACGIH recommended BEI indicates that the
threshold of 400mg/g creatinine may not protect workers
from the consequences of styrene exposure. Furthermore, the
excess of acquired color-blindness, though not associated
with styrene biomarkers, suggests that health effects may be
a consequence of relatively low styrene exposures. The
association of cumulative exposure with certain outcomes
indicates that there are effects, particularly on respiratory
health, that are not attributable to current styrene exposure
only. Further studies may help to determine an effect
threshold for these health outcomes and provide guidance
toward targets for exposure reduction. Additionally, such
studies could further elucidate the relationship between
airways disease, inflammation, and styrene.
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Supplement Material 
Methods 
Analysis of styrene metabolites:  
Spot urine samples collected from workers were stored at -70 °C until the assay. An 
aliquot of 50 µl of each sample was assayed for 29 volatile organic metabolites using an ultra 
high performance liquid chromatography system (Waters Inc., Milford, MA) coupled with 
electro spray tandem mass spectrometry (Sciex API 5500 Triple Quad, Applied Biosystems, 
Foster City, CA) method (UPLC/ESI-MSMS) [Alwis et al. 2004]. Urine samples were assayed at 
1:10 dilution (50 µL urine + 25 µL working mixed internal standard + 425 µL 15 mM ammonium 
acetate). A mixture of 28 internal standards labeled with stable isotopes was used to normalize 
the results. Chromatographic separation was achieved using an Acquity UPLC® HSS T3 1.8 µm x 
2.1 mm x 150 mm (Waters Inc, Milford, MA) column with 15 mM ammonium acetate pH 6.8 
(Solvent A) and acetonitrile (Solvent B) as mobile phases. The eluent from the column was 
ionized using an electrospray interface to generate and transmit negative ions into the mass 
spectrometer. Comparison of relative response factors (ratio of native analyte to stable isotope 
labeled internal standard) with known standard concentrations yielded individual analyte 
concentrations for unknowns. The Analyst software (version 1.5.1, Applied Biosystems, Foster 
City, CA) was used to operate both the UPLC and the API5500 triple quadrupole.  The mass 
spectrometer was operated under scheduled multiple reaction monitoring (SMRM) mode for 
negative ions, the ion source temperature was kept at 650°C, and the electro spray ion voltage 
at -4000 V. The mass parameters were optimized for each analyte. For PHEMA, m/z 282/153 
and m/z 282/123, for MA m/z 151/107 and m/z 152/108, and for PGA m/z 149/77 and m/z 
149/105 were monitored as quantitation and confirmation ion transitions respectively.  We 
monitored  m/z 288/159 for PHEMA_13C6, m/z 156/112 for MA_D5 and m/z 154/82 for 
PGA_D5. The limit of detection (LOD) for PHEMA 0.7 ng/mL and for MA and PGA was 12 ng/mL. 
 
Analysis of urine creatinine:  
The urine creatinine was assayed by an enzyme colorimetric method using the 
automated Roche/Hitachi Modular Analytics system. The color intensity produced was 
measured by a multiple wavelength spectrophotometer with a 12 volt tungsten halogen lamp 
as the light source. The wavelengths read for this assay were 546 and 700 nm. The color 
intensity produced is directly proportional to the concentration of creatinine in the sample. This 
method is standardized against isotope dilution mass spectrometry method (ID-MS). The lower 
detection limit of this colorimetric method is 0.6 mg/dL. 
 
 
